Andrew Huberman: Now they have a second study
Understanding these genetic insights helps PlexusDx clinicians select the optimal compound and dosing strategy, potentially reducing overall side-effect burden and improving injection tolerance
Various dual/triple agonists for glucagon-like peptide-1 receptor (GLP-1R), which also target the gastric inhibitory peptide receptor and glucagon receptor, have recently been explored to increase treatment efficacy for both diabetes and obesity in the clinical setting [9, 10]
Further reading and references Wilding et al: Once-Weekly Semaglutide in Adults with Overweight or Obesity Moiz et al: Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes Rubino et al: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Bolek et al: Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity About the authorView full bio Dr Nienke Lees Women's Health Service Lead MB BChir, MA, MRCS(ENT), DOHNS, MRCGP, LMCA Dr Nienke Lees is the Women's Health Service Lead at Genwell
[1] This is Novo Nordisk's official list price before any discounts are applied
Klinkhammer C et al
